Moderna mRNA vaccine almost halves risk of melanoma returning
⏮ BeforeTreatment-resistant melanoma often returns after treatment.
✅ NowIn a phase III trial, an mRNA vaccine almost halved the risk of return.
In short
- Results from a phase III trial were published in Nature on 23 October 2026.
- The vaccine was tested in patients with treatment-resistant melanoma.
- The source describes the benefit as huge, and the trial results are now public.
Why the Good News Desk likes this one
Melanoma that resists treatment is among the hardest skin cancers to hold back. A phase III trial is the large, final test before regulators decide on approval. The source reports that the vaccine almost halves the chance of recurrence, though the wider approval path is not described in the text.
Advertisement
From Nature
Nature, Published online: 23 October 2026; doi:10.1038/d41586-026-03417-0 Long-awaited results from phase III trial show huge benefits for treatment-resistant melanoma.
Ask this story
📜 The story so far
- 22 Oct 2026 Personalized Cancer Vaccine Cuts Melanoma Recurrence Risk by 42 Percent Where it started.
- 23 Oct 2026 Moderna mRNA vaccine almost halves risk of melanoma returning The same Moderna melanoma vaccine trial result is now described as almost halving recurrence risk, a rephrasing of the earlier 42 percent figure rather than a new development.
- 23 Oct 2026 Personalized mRNA vaccine cuts melanoma recurrence risk in late-stage trial The same personalized mRNA melanoma vaccine's 42% recurrence-risk reduction is now reported from a late-stage trial, with the risk figure restated as death too.
- 23 Oct 2026 Moderna and Merck personalised melanoma vaccine cuts recurrence in trial The same Moderna and Merck melanoma vaccine trial is reported again, now describing delayed return and spread of the cancer in the trial data.
- 23 Oct 2026 Personalised mRNA cancer vaccine cuts melanoma return risk by 42% The same 42% melanoma result is now reported with more detail, adding that it is a Phase III trial of the Keytruda-combined vaccine.
More like this
Advertisement